Skip to content

Evaluating an e-mental health program ('deprexis') as adjunctive treatment tool in psychotherapy for depression

Evaluating an e-mental health program ('deprexis') as adjunctive treatment tool in psychotherapy for depression: design of a pragmatic randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN20165665
Enrollment
800
Registered
2014-06-03
Start date
2014-04-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorders Mental and Behavioural Disorders

Interventions

1. Intervention group: Psychotherapy plus web-based online platform (deprexis): Participants in the intervention group receive access to the deprexis platform. Trained, certified psychotherapists int

Sponsors

Swiss National Science Foundation (Switzerland)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We include adults 1. Aged 18 or over 2. Suffer from a MDD according to the International Classification of Diseases (ICD-10; i.e., F32.-depressive episode, F33.- Recurrent Depressive Disorder, F34.- Persistent Affective Disorder, F38.- Other Affective Disorder, F39 Unspecified Affective Disorder) 3. Who have a Beck Depression Inventory (BDI-II) sum score over 13 4. Who have sufficient knowledge of the German language 5. Who have Internet access and sufficient knowledge to use it (based on self-report) 6. Who are willing to give informed consent

Exclusion criteria

Exclusion criteria: We will exclude subjects who: 1. Have a known psychotic or bipolar disorder 2. Suffer from a chronic depression with onset in childhood (based on clinical judgment) 3. Show a notable suicidal risk (based on clinical judgment of the therapists)

Design outcomes

Primary

MeasureTime frame
Depressive symptomatology as measured with the Beck Depression Inventory (BDI-II). Timepoints of assessment: pretreatment, posttreatment (12 weeks), follow-up (6 months)

Secondary

MeasureTime frame
Measures 1 to 7 are assessed at pretreatment, posttreatment (12 weeks), and at follow-up (6 months) 1. Symptoms of anxiety assessed with the German version of the 7-item Generalized Anxiety Disorder Scale (GAD-7) 2. Somatic symptomatology as assessed with the somatic symptom module of the Patient Health Questionnaire (PHQ) 3. Quality of life assessed with the Short-Form Health Survey-12 (SF-12) 4. Questionnaire for the evaluation of psychotherapeutic progress (FEP-2) to measure the dimensions well-being, symptoms, interpersonal relationships, and incongruence with respect to approach and avoidance goals 5. Web Screening Questionnaire (WSQ) to screen for common mental disorders. The WSQ is a 15-item self-report instrument screening for frequent mental disorders 6. Suicidal tendencies as assessed with the Suicidal Behaviours Questionnaire-Revised (SBQ-R) 7. Psychological empowerment as assessed with an adapted version of the scale by Spreitzer 8. Depression diagnosis as assessed by the licenced therapists conducting the treatment (only pre-and posttreatment) 9. Working Alliance Inventory ? Short (WAI-S; adapted version) as assessed by patients and therapists (week 6; week 12)

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 7, 2026